10 completed, 4 recruiting, 1 not yet recruiting, 1 suspended. 7 Phase 1, 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Recruiting 1, Unknown 1 |
| Phase 2 | 6 | Recruiting 3, Completed 1, Suspended 1, Withdrawn 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Lassa Fever: new trials by email Literature Review of Lassa Fever trials Research Report on Lassa Fever
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA FORTIFIEDx and DECIPHER bioassays - Ebola Hemorrhagic Fever, Lassa Hemorrhagic Fever | Not yet recruiting | Institute of Tropical Medicine, Belgium | 150 | 2027-01-01 | 2026-07-02 | |
| A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever Low dose MOPEVAC-Las vaccine, Intermediate dose MOPEVAC-Las vaccine, High dose MOPEVAC-Las vaccine - Lassa Fever | Phase 1 | Recruiting | Institut Pasteur | 72 | 2026-09-28 | 2026-10-13 |
| ARN-75039 Lassa Fever Treatment in West Africa ARN-75039 high, Intravenous ribavirin, ARN-75039 low - Lassa Fever | Phase 2 | Suspended | Arisan Therapeutics, Inc. | 135 | 2026-02-14 | 2026-07-06 |
| ISTH/ANRS 0409s INTEGRATE Lassa Fever Study Favipiravir, Ribavirin, Dexamethasone - Lassa Fever | Phase 2 / Phase 3 | Recruiting | Irrua Specialist Teaching Hospital | 1755 | 2025-05-02 | 2026-02-04 |
| DMID 23-0015; Lassa Fever CVD 1000 LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo - Lassa Fever | Phase 1 | Completed | Wilbur Chen, MD, MS | 54 | 2025-01-13 | 2026-09-24 |
| A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa Day 1 Dose (2×106 pfu), Day 1 Dose (1×107 pfu), Placebo - Lassa Fever | Phase 2 | Recruiting | International AIDS Vaccine Initiative | 530 | 2024-03-06 | 2026-10-23 |
| LAssa Fever Adjunct Treatment With DEXamethasone Dexamethasone, Ribavirin - Lassa Fever | Phase 2 | Recruiting | Bernhard Nocht Institute for Tropical Medicine | 42 | 2024-02-05 | 2025-02-06 |
| Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever Ribavirin iv, Favipiravir - Lassa Fever | Phase 2 | Completed | Bernhard Nocht Institute for Tropical Medicine | 40 | 2021-07-30 | 2023-02-08 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath rVSV∆G-LASV-GPC, Placebo/Diluent - Lassa Fever, Lassa Virus Infection | Phase 1 | Unknown | International AIDS Vaccine Initiative | 114 | 2021-06-23 | 2024-01-18 |
| Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana INO-4500, CELLECTRA™ 2000, Placebo - Lassa Fever | Phase 1 | Completed | Inovio Pharmaceuticals | 220 | 2021-01-27 | 2022-11-21 |
| Prevalence and Incidence of Lassa Virus Infection in Southern Mali Lassa Virus Infection | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 8524 | 2020-12-04 | 2026-08-28 | |
| Cardiovascular Function and Ribavirin PK/PD in Lassa Fever in Lassa Fever Lassa Fever | Completed | University of Oxford | 158 | 2019-11-26 | 2021-10-13 | |
| A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001) MV-LASV, Placebo - Lassa Virus Infection | Phase 1 | Completed | Themis Bioscience GmbH | 60 | 2019-09-26 | 2025-07-11 |
| Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants LHF-535 - Healthy | Phase 1 | Completed | Kineta Inc. | 24 | 2019-09-16 | 2020-07-09 |
| Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers INO-4500, Placebo, CELLECTRA® 2000 - Lassa Fever | Phase 1 | Completed | Inovio Pharmaceuticals | 60 | 2019-05-09 | 2020-11-23 |
| Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever Ribavirin - Lassa Fever | Terminated | University of Oxford | 2 | 2019-03-01 | 2022-07-06 | |
| Lassa Fever Clinical Course and Prognostic Factors in Nigeria Non interventional research - Lassa Fever, Lassa Virus Infection | Completed | Alliance for International Medical Action | 1100 | 2018-04-05 | 2026-10-28 | |
| Seroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali Lassa Virus Infection | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 601 | 2014-12-05 | 2019-12-12 | |
| Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities Ribavirin (Virazole) Injection - Crimean-Congo Hemorrhagic Fever, Lassa Fever | Phase 2 | Withdrawn | U.S. Army Medical Research and Development Command | 2009-09-01 | 2020-01-02 |
Hemorrhagic Fevers, Viral (5) · Communicable Diseases, Emerging (2) · Acute Kidney Injury (1) · Coma (1) · Fever (1) · HIV Seropositivity (1) · Hemorrhagic Fever, Crimean (1) · Hemorrhagic Fever, Ebola (1) · Neglected Diseases (1) · Pregnancy Complications (1)
Arenaviridae Infections (19) · Infections (19) · RNA Virus Infections (19) · Virus Diseases (19) · Hemorrhagic Fevers, Viral (14) · Pathological Conditions, Signs and Symptoms (4) · Communicable Diseases (3) · Disease Attributes (2) · Pathologic Processes (2) · Signs and Symptoms (2) · Urogenital Diseases (2) · Arbovirus Infections (1) · Blood-Borne Infections (1) · Body Temperature Changes (1) · Bunyaviridae Infections (1)
Ribavirin (4) · Dexamethasone (2) · Injections (2) · favipiravir (2) · Rabies Vaccines (1) · Saline Solution (1) · Standard of Care (1)
Bernhard Nocht Institute for Tropical Medicine (2) · Inovio Pharmaceuticals (2) · International AIDS Vaccine Initiative (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University of Oxford (2) · Alliance for International Medical Action (1) · Arisan Therapeutics, Inc. (1) · Institut Pasteur (1) · Institute of Tropical Medicine, Belgium (1) · Irrua Specialist Teaching Hospital (1) · Kineta Inc. (1) · Themis Bioscience GmbH (1) · U.S. Army Medical Research and Development Command (1) · Wilbur Chen, MD, MS (1)
Nigeria (7) · United States (4) · Liberia (3) · Ghana (2) · Mali (2) · Australia (1) · Belgium (1) · France (1) · Germany (1) · Sierra Leone (1)
Heinrich U Feldmann, M.D. (2) · Alex Salam, MD (1) · Alimou Camara, Dr. (1) · Bonaventure Orizu, MD (1) · Denis Malvy, MD, PhD (1) · Elizabeth Rini, MD (1) · Karifa Kourouma, MD, MSc (1) · Ken McCormack, PhD (1) · Koen Vercauteren, Dr. Prof. (1) · Mammen Mammen, MD, FACP, FIDSA (1) · Oladele O Ayodeji, MD (1) · Oluwafemi Ayodeji, Dr (1)
PMID 31978611, PMID 36934733, PMID 41191941, PMID 41208990, PMID 42141199, PMID 42265408
2018 (1), 2023 (1)